# Risk Factors of Immune-ChEckpoint Inhibitors MEdiated Liver, Gastrointestinal, Endocrine and Skin Toxicity

> **NCT04631731** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Western Sydney Local Health District** · enrollment: 200 (estimated)

## Conditions studied

- Lung Cancer, Nonsmall Cell
- Renal Cell Carcinoma
- Melanoma
- Gastric Cancer
- Hepatocellular Carcinoma
- Endometrial Cancer
- Mesothelioma

## Interventions

- **DIAGNOSTIC_TEST:** Blood screening
- **DIAGNOSTIC_TEST:** Tissue screening

## Key facts

- **NCT ID:** NCT04631731
- **Lead sponsor:** Western Sydney Local Health District
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-12-15
- **Primary completion:** 2024-12-10
- **Final completion:** 2025-12-10
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2023-06-01

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04631731

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04631731, "Risk Factors of Immune-ChEckpoint Inhibitors MEdiated Liver, Gastrointestinal, Endocrine and Skin Toxicity". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04631731. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*